BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, May 10, 2024
See today's BioWorld
Home
» 2nd Zealand, Boehringer Ingelheim diabetes deal worth up to $396M
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
2nd Zealand, Boehringer Ingelheim diabetes deal worth up to $396M
July 29, 2014
By
Cormac Sheridan
No Comments
Zealand Pharma A/S could earn up to €295 million (US$396 million) in milestone payments arising from a second drug development deal in diabetes with Boehringer Ingelheim GmbH. It will bank €5.6 million during 2014.
BioWorld